GRI Bio (NASDAQ:GRI) Releases Earnings Results

GRI Bio (NASDAQ:GRIGet Free Report) issued its earnings results on Friday. The company reported -0.46 EPS for the quarter, reports.

GRI Bio Stock Performance

GRI Bio stock opened at 0.41 on Monday. GRI Bio has a 12 month low of 0.38 and a 12 month high of 49.28. The stock’s 50 day simple moving average is 0.61 and its two-hundred day simple moving average is 2.57.

GRI Bio Company Profile

(Get Free Report)

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

See Also

Earnings History for GRI Bio (NASDAQ:GRI)

Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with's FREE daily email newsletter.